Related Experiment Video
Updated: Aug 16, 2026
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
Acute nonlymphocytic leukemia in 171 children
Insights
Childhood acute non-lymphoblastic leukemia (ANLL) shows distinct features from adult ANLL and acute lymphoblastic leukemia (ALL). Current treatments yield unsatisfactory outcomes, highlighting the need for novel ANLL therapies.
Area of Science:
- Pediatric Hematology Oncology
- Leukemia Research
- Clinical Trial Analysis
Background:
- Acute non-lymphoblastic leukemia (ANLL) in children presents unique clinical and prognostic characteristics compared to adults and acute lymphoblastic leukemia (ALL).
- Understanding these differences is crucial for developing targeted and effective treatment strategies for pediatric ANLL.
Purpose of the Study:
- To describe initial features, treatment response, complications, mortality, and prognostic factors in 171 children with ANLL.
- To compare these findings with historical data for adult ANLL and childhood ALL.
- To evaluate the impact of updated therapeutic protocols on remission and survival rates.
Main Methods:
- Retrospective analysis of 171 consecutive pediatric ANLL cases.
- Comparison with historical data for adult ANLL and childhood ALL.
- Evaluation of treatment outcomes based on different therapeutic protocols implemented since 1968.
Main Results:
- Children with ANLL exhibit higher CNS leukemia frequency and lower early death rates than adults with ANLL.
- Childhood ANLL lacks a peak incidence age and shows a poorer response to therapy compared to childhood ALL.
- Improved protocols since 1968 increased remission frequency (66%) but median remission (6 months) and survival (10 months) remain unsatisfactory.
Conclusions:
- Significant differences exist between pediatric ANLL, adult ANLL, and pediatric ALL, necessitating distinct treatment approaches.
- Current therapeutic protocols for childhood ANLL yield suboptimal outcomes, emphasizing the urgent need for innovative treatment strategies.
- Favorable prognostic indicators include WBC counts ≥100,000/mm³, absence of hepatomegaly, and higher platelet counts.
Abstract:
The initial features, response to therapy, complications, cause of death, and prognostic factors of 171 consecutive children with ANLL are described and compated to historical data for adults with ANLL and for children with ALL. Major differences between children and adults with ANLL include a higher frequency of CNS leukemia and a lower frequency of early deaths in the children. The most important differences between children with ANLL and ALL are the absence of a peak age of incidence in ANLL and the far better response to therapy in ALL. Among features present at 100,000/mm3 or above, and no palpable hepatomegaly had significantly longer survivals, while patients with platelet counts below 10,000/mm3 had significantly shorter survivals. The frequency and duration of remission were significantly better with three protocols used since 1968 than previously. However, even with these protocols, the results were far from satisfactory, with a complete remission frequency of 66%, a median duration of hematological remission of 6 months, and a median duration of survival of 10 months. The striking contrast of these results in childhood ANLL with current results in childhood ALL underscores the need for novel, imaginative therapeutic approaches for ANLL.
